CITIUS ONCOLOGY, INC. — fact timeline

CITIUS ONCOLOGY, INC. reported the fiscal second quarter ended March 31, 2026 results: revenue $1.7 million.

“revenue milestones; and, ○ approximately $11.5 million in gross proceeds received May 5, 2026 from the exercise of certain outstanding warrants; and, ● Net product revenues of $1.7 million for the three months ended March 31, 2026, compared to no revenue for the three months ended March 31, 2025; and $5.6 million for the six months ended March 31, 2026, compared”

CITIUS ONCOLOGY, INC. entered into Warrant Inducement Agreement with the holder of certain existing warrants valued at approximately $11.5 million (effective 2026-05-05).

“On May 5, 2026, Citius Oncology, Inc. (the “Company”), entered into a warrant inducement agreement (the “Warrant Inducement Agreement”) with the holder of certain existing warrants”

CITIUS ONCOLOGY, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“April 22, 2026, Nasdaq Stock Market LLC (“Nasdaq”) notified Citius Oncology, Inc. (the “Company”) that for the last 30 consecutive business days, the bid price for the Company’s common stock had closed below the minimum”

CITIUS ONCOLOGY, INC. entered into Registration Rights Agreement with the investor valued at Company agreed to file a registration statement for resale of shares issuable upon exercise of Pre-f (effective 2025-12-08).

“In connection with the PIPE Purchase Agreement, the Company entered into a registration rights agreement with the investor (the “Registration Rights Agreement”).”

CITIUS ONCOLOGY, INC. entered into PIPE Purchase Agreement with such institutional investor valued at issuance of Pre-funded Warrants to purchase up to 15,229,358 shares and Common Warrants to purchase (effective 2025-12-08).

“On December 8, 2025, the Company also entered into a securities purchase agreement (the “PIPE Purchase Agreement”, together with the RD Purchase Agreement, the “Purchase Agreements”) with such institutional investor to issue in a concurrent private placement pre-funded warrants to purchase up to 15,229,358 shares of common stock (the “Pre-funded Warrants”) and 15,229,358 Common Warrants, at a combined price of $1.0899 per Pre-funded Warrant and accompanying Common Warrant.”

CITIUS ONCOLOGY, INC. entered into RD Purchase Agreement with a certain institutional investor valued at purchase and sale of 1,284,404 shares of common stock at $1.09 per share, plus Common Warrants to pu (effective 2025-12-08).

“On December 8, 2025, Citius Oncology, Inc. (the “Company”) entered into a securities purchase agreement (the “RD Purchase Agreement”) with a certain institutional investor in a registered direct offering for the purchase and sale of 1,284,404 shares of our common stock, $0.0001 par value per share, at an offering price of $1.09 per share of common stock (the “Shares”).”

CITIUS ONCOLOGY, INC. issued up to 1,155,963 shares of common stock of warrant to H.C. Wainwright and Co., LLC.

“In addition, the Company granted placement agent warrants to Wainwright, or its designees, to purchase up to 1,155,963 shares of common stock (the “Placement Agent Warrants”)”

CITIUS ONCOLOGY, INC. issued 15,229,358 Common Warrants of warrant to such institutional investor for at a combined price of $1.0899 per Pre-funded Warrant and accompanying Common Warrant.

“to issue in a concurrent private placement pre-funded warrants to purchase up to 15,229,358 shares of common stock (the “Pre-funded Warrants”) and 15,229,358 Common Warrants, at a combined price of $1.0899 per Pre-funded Warrant and accompanying Common Warrant”

CITIUS ONCOLOGY, INC. issued pre-funded warrants to purchase up to 15,229,358 shares of common stock of warrant to such institutional investor for at a combined price of $1.0899 per Pre-funded Warrant and accompanying Common Warrant.

“On December 8, 2025, the Company also entered into a securities purchase agreement (the “PIPE Purchase Agreement”, together with the RD Purchase Agreement, the “Purchase Agreements”) with such institutional investor to issue in a concurrent private placement pre-funded warrants to purchase up to 15,229,358 shares of common stock (the “Pre-funded Warrants”) and 15,229,358 Common Warrants, at a combined price of $1.0899 per Pre-funded Warrant and accompanying Common Warrant”

CITIUS ONCOLOGY, INC. issued warrants to purchase up to 1,284,404 shares of common stock of warrant to such institutional investor for at a combined price of $1.0899 per Pre-funded Warrant and accompanying Common Warrant.

“In a concurrent private placement, the Company also agreed to sell such institutional investor warrants to purchase up to 1,284,404 shares of common stock (the “Common Warrants”), with an exercise price of $1.09 per share of our common stock”

CITIUS ONCOLOGY, INC. issued 1,284,404 shares of common stock to a certain institutional investor for $1.09 per share.

“On December 8, 2025, Citius Oncology, Inc. (the “Company”) entered into a securities purchase agreement (the “RD Purchase Agreement”) with a certain institutional investor in a registered direct offering for the purchase and sale of 1,284,404 shares of our common stock, $0.0001 par value per share, at an offering price of $1.09 per share of common stock”

CITIUS ONCOLOGY, INC. issued up to 360,000 shares of common stock of warrant to a financial advisor.

“On September 19, 2025, Citius Oncology, Inc. (the “Company) issued to a financial advisor warrants to purchase up to 360,000 shares of our common stock with an exercise price of $2.1875 per shares, that are exercisable on March 10, 2026, and that expire on March 10, 2031.”

CITIUS ONCOLOGY, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“April 23, 2025, Nasdaq Stock Market LLC (“Nasdaq”) notified Citius Oncology, Inc. (the “Company”) that for the last 30 consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has a compliance period of 180 calendar days, or until October 20, 2025, to regain compliance with the Bid Price Rule. If at any time before October 20, 2025, the bid”

CITIUS ONCOLOGY, INC. underwent a change of control involving Citius Pharmaceuticals, Inc., TenX Keane Acquisition (closed 2024-08-12).

“on August 12, 2024 (the "Closing Date"), the Company completed the previously announced business combination (the "Closing") pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of October 23, 2023, by and among Citius Pharmaceuticals, Inc., a Nevada corporation, Citius Oncology Sub, Inc., a Delaware corporation ("SpinCo"), TenX Keane Acquisition, a Cayman Islands exempted company ("TenX", now Citius Oncology, Inc., a Delaware corporation) and TenX Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of TenX, and the related transaction documents described therein (the "Business Combination").”

CITIUS ONCOLOGY, INC. underwent a change of control involving Citius Pharmaceuticals, Inc. (closed 2024-08-12).

“On August 12, 2024 (the “Closing Date”), the Company completed the previously announced business combination (the “Closing”) pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of October 23, 2023 (the “Merger Agreement”), by and among Citius Pharmaceuticals, Inc., a Nevada corporation (“Citius Pharma”), Citius Oncology, Inc., a Delaware corporation (now known as Citius Oncology Sub, Inc., “SpinCo”), TenX (now Citius Oncology, Inc., a Delaware corporation) and TenX Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of TenX (“Merger Sub”), and the related transaction documents described therein (the “Business Combination”).”

Brian Hartzband resigned as Director at CITIUS ONCOLOGY, INC..

“each of Cathy Jiang and Brian Hartzband resigned as directors”

Cathy Jiang resigned as Director at CITIUS ONCOLOGY, INC..

“each of Cathy Jiang and Brian Hartzband resigned as directors”

Taylor Zhang resigned as Chief Financial Officer at CITIUS ONCOLOGY, INC..

“Taylor Zhang resigned as Chief Financial Officer and a director”

Xiaofeng Yuan resigned as Chief Executive Officer at CITIUS ONCOLOGY, INC..

“Xiaofeng Yuan resigned as Chief Executive Officer and Chairman of the Board”

CITIUS ONCOLOGY, INC. incurred loan of principal amount of $66,667 with Citius Pharma at no interest maturing repayable in full per the terms of the Merger Agreement.

“On April 26, 2024, Citius Pharma deposited $66,667 into the trust account of the Company (the "Contribution") to extend the timeline to complete a business combination for an additional one (1) month period from April 18, 2024 to May 18, 2024 (the "Extension"). Such deposit of the Contribution is evidenced by an unsecured promissory note (the "Note") issued by the Company in the principal amount of $66,667 to Citius Pharma. The Note bears no interest and is repayable in full per the terms of the Merger Agreement.”

CITIUS ONCOLOGY, INC.: Shareholders approved amendment to Amended and Restated Memorandum and Articles of Association to extend the combination period in up to eight installments, from January 2024 to November 2024 (effective 2024-01-17).

“On January 17, 2024, the Company held the Meeting, in lieu of the 2023 annual general meeting, at which the Company’s shareholders approved (i) a proposal, by special resolution, to amend the Company’s Amended and Restated Memorandum and Articles of Association in their entirety and the substitution in their place of the third amended and restated memorandum and articles of association of the Company (the “ Third A&R Memorandum and Articles ”), which provides that the Company may elect to extend the date by which the Company has to consummate a business combination (the “ Combination Period ”) for a total of eight (8) times, as follow: (a) one (1) time for an additional three (3) months from January 18, 2024 to April 18, 2024, and subsequently (b) seven (7) times for an additional one (1) month each time from April 18, 2024 to November 18, 2024, if requested by the Sponsor and upon two calendar days’ advance notice prior to the applicable deadline”

CITIUS ONCOLOGY, INC. shareholders approved Auditor Ratification Proposal.

“The shareholders approved the Extension Amendment Proposal and the Auditor Ratification Proposal.”

CITIUS ONCOLOGY, INC. shareholders approved Extension Amendment Proposal.

“The shareholders approved the Extension Amendment Proposal and the Auditor Ratification Proposal.”

CITIUS ONCOLOGY, INC. incurred loan of $200,000 with Citius Pharma at no interest maturing repayable in full per the terms of the Merger Agreement.

“the Company issued a promissory note to Citius Pharma with a principal amount of $200,000 (the “ Note ”). The Note bears no interest and is repayable in full per the terms of the Merger Agreement.”

CITIUS ONCOLOGY, INC. entered into Promissory Note with Citius Pharmaceuticals, Inc. valued at 200,000 (effective 2024-01-17).

“ub ”), Citius Pharmaceuticals, Inc., a Nevada corporation (“ Citius Pharma ”), and Citius Oncology, Inc., a Delaware corporation and wholly owned subsidiary of Citius Pharma (“ Citius Oncology ”), to acquire Citius Oncology.”

CITIUS ONCOLOGY, INC. entered into Agreement and Plan of Merger and Reorganization with TenX Keane Acquisition, TenX Merger Sub, Inc., Citius Pharmaceuticals, Inc. (effective 2023-10-23).

“On October 23, 2023, TenX Keane Acquisition, a Cayman Islands exempted company (“ TenX ”), entered into an Agreement and Plan of Merger and Reorganization (the “ Merger Agreement” ), by and among TenX, TenX Merger Sub, Inc., a Delaware corporation and wholly owned Subsidiary of TenX (“ Merger Sub ”), Citius Pharmaceuticals, Inc., a Nevada corporation (“ Citius Pharma ”), and Citius Oncology, Inc., a Delaware corporation and wholly owned subsidiary of Citius Pharma (“ Citius Oncology ”).”

CITIUS ONCOLOGY, INC. incurred loan of $660,000 with 10XYZ Holdings LP at no interest maturing due upon consummation of business combination.

“On October 18, 2023, the Company deposited $660,000 into the trust account of the Company (the “Extension Fee”) to extend the timeline to complete a business combination for an additional three months from October 18, 2023 to January 18, 2024 (the “Extension”). Such deposit of the Extension Fee is evidenced by an unsecured promissory note (the “Promissory Note”) in the principal amount of $660,000 to the Sponsor.”

CITIUS ONCOLOGY, INC. incurred convertible notes of $660,000 with 10XYZ Holdings LP at bears no interest maturing upon the consummation of the Company's business combination.

“On July 18, 2023, the Company deposited $660,000 into the trust account of the Company (the “Extension Fee”) to extend the timeline to complete a business combination for an additional three months from July 18, 2023 to October 18, 2023 (the “Extension”). Such deposit of the Extension Fee is evidenced by an unsecured promissory note (the “Promissory Note”) in the principal amount of $660,000 to the Sponsor. The Promissory Note bears no interest and is payable in full upon the consummation of the Company’s business combination (such date, the “Maturity Date”).”